Health authorities have decided to prioritize semaglutide for further clinical validation in patients with non-alcoholic fatty liver disease (NAFLD) suffering from severe hyperlipidemia. Strong mechanistic support and promising early results, including an eightfold reduction in triglyceride levels and nearly a twofold decrease in cholesterol, have led to a low-risk posture for its deployment. Meanwhile, ongoing data collection will enhance the confidence in the drug's broader therapeutic potential.